Tango Therapeutics Inc
TNGX6.590USD
+0.060+0.92%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
712.43MCap. mercado
PérdidaP/E TTM
Más Datos de Tango Therapeutics Inc Compañía
Tango Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering precision medicine for the treatment of cancer. The Company leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. This includes expanding the universe of precision oncology targets into novel areas such as tumor suppressor gene loss and their contribution to the ability of cancer cells to evade immune cell killing. Its lead program, TNG908, is an methylthioadenosine (MTA)-cooperative inhibitor of protein arginine methyltransferase 5 (PRMT5) designed to work selectively in cancer cells with an methylthioadenosine phosphorylase (MTAP) deletion. Its TNG260 is a first-in-class Co-repressor of Repressor Element-1 Silencing Transcription (CoREST) inhibitor. The Company's programs also include TNG348 and TNG462. TNG348 is an allosteric inhibitor of ubiquitin-specific protease (USP1).
Información de la empresa
Símbolo de cotizaciónTNGX
Nombre de la empresaTango Therapeutics Inc
Fecha de salida a bolsaSep 03, 2020
Director ejecutivoDr. Barbara Weber, M.D.
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 03
Dirección201 Brookline Avenue
CiudadBOSTON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal02215
Teléfono18573204900
Sitio Webhttps://www.tangotx.com/
Símbolo de cotizaciónTNGX
Fecha de salida a bolsaSep 03, 2020
Director ejecutivoDr. Barbara Weber, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
Accionistas
Accionistas
Proporción
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
34.87%
Hedge Fund
24.69%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
16.29%
Corporation
11.03%
Individual Investor
1.57%
Research Firm
1.15%
Family Office
0.65%
Private Equity
0.51%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
311
118.45M
109.28%
-17.53M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
2023Q1
216
83.27M
94.51%
-3.16M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Third Rock Ventures, LLC
16.86M
15.55%
-194.17K
-1.14%
Apr 01, 2025
TCG Crossover Management, LLC
10.74M
9.9%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
10.63M
9.81%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
10.38M
9.58%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
7.18M
6.63%
+2.57M
+55.76%
Jun 06, 2025
Nextech Invest, Ltd.
5.53M
5.11%
--
--
Mar 31, 2025
Gilead Sciences Inc
4.85M
4.48%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
3.58%
-98.30K
-2.47%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.74M
3.45%
-110.35K
-2.87%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.31M
3.06%
-33.10K
-0.99%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
Ver más
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.91%
iShares Micro-Cap ETF
Proporción0.08%
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
iShares Biotechnology ETF
Proporción0.03%
ProShares UltraPro Russell2000
Proporción0.02%
Global X Russell 2000 ETF
Proporción0.02%
iShares Russell 2000 Value ETF
Proporción0.02%
Proshares Ultra Russell 2000
Proporción0.02%
ProShares Hedge Replication ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
